AstraZeneca's Symbicort is racing toward patent expiration. But on Thursday, the company won six more months of exclusivity for the asthma and COPD inhaler. (Photo by Jonathan Ferrey/Getty Images) ...
The victory marks the fourth Symbicort patent deemed invalid or not infringed in court, Viatris and Kindeva pointed out. (Viatris) In the courtroom fracas over the patents on AstraZeneca’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results